Results
Title

Effect of temozolomide on male gametes: an epigenetic risk to the offspring?

Authors

Berthaut, I.; Montjean, D.; Dessolle, L.; Morcel, K.; Deluen, F.; Poirot, C.; Bashamboo, A.; Mcelreavey, K.; Ravel, C.

Abstract

Introduction: Temozolomide is an oral alkylating agent with proven efficacy in recurrent high-grade glioma. The antitumour activity of this molecule is attributed to the inhibition of replication through DNA methylation. However, this methylation may also perturb other DNA-dependent processes, such as spermatogenesis. The ability to father a child may be affected by having this treatment. Here we report a pregnancy and a baby born after 6 cures of temozolomide. Methods: The quality of gametes of the father has been studied through these cures and after the cessation of treatment. Sperm parameters, chromosomal content and epigenetic profiles of H19, MEST and MGMT have been analysed. Results: Sperm counts decrease significantly and hypomethylation of the H19 locus increase with time even staying in the normal range. Conclusion: This is the first report of an epigenetic modification in sperm after temozolomide treatment suggesting a potential risk for the offspring. A sperm cryopreservation before the initiation of temozolomide treatment should be recommended.

Subjects

ALKYLATING agents; GLIOMA treatment; DNA replication; PREGNANCY; SPERMATOZOA; CRYOPRESERVATION of organs, tissues, etc.; EPIGENETICS; GAMETES

Publication

Journal of Assisted Reproduction & Genetics, 2013, Vol 30, Issue 6, p827

ISSN

1058-0468

Publication type

Academic Journal

DOI

10.1007/s10815-013-9999-8